Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Fate Therapeutics Inc.
Headquarters: San Diego, CA, United States of America
Website: http://www.fatetherapeutics.c...
Year Founded: 2007
Status: Public
Industry Sector: HealthTechnology
CEO: Bahram Valamehr, PhD, MBA
Number Of Employees: 181
Enterprise Value: $-6,219,458
PE Ratio: -0.55
Exchange/Ticker 1: NASDAQ:FATE
Exchange/Ticker 2: N/A
Latest Market Cap: $103,802,000
BioCentury | Dec 3, 2024
Management Tracks
Bob Valamehr to succeed CEO Scott Wolchko at Fate
Plus: Amoolya Singh named CTO of Delfi and updates from Torl, OSE and George Clinical
BioCentury | Aug 20, 2024
Management Tracks
Toraishi steps down from Rakuten Medical as co-CEO
Plus: SalioGen hired Kalliopi Stasi as CMO and updates from PepGen, Cidara and Bio-Rad
BioCentury | Jun 28, 2024
Management Tracks
Forbion taps Dyne vet Brumm to guide growing U.S. presence
Plus: Edward Dulac to become CFO at Intellia, and updates from Altimmune, Bayer, Compass, Sensorion and Neurona
BioCentury | May 3, 2024
Discovery & Translation
CAR T cells: Cancer, autoimmunity, and beyond?
ASGCT abstracts highlight applications for CAR Ts outside of cancer
BioCentury | Apr 4, 2024
Management Tracks
Upstream names new CEO, CFO and COO
Plus: Acadia hires Elizabeth Thompson as head of R&D, and updates from Insitro, Fractyl, Adarx and more
BioCentury | Feb 16, 2024
Product Development
Creating CAR T therapies that don’t cause cancer
Off switches and non-viral delivery technologies may be the solution to CAR Ts’ most recent safety problem
BioCentury | Dec 23, 2023
Discovery & Translation
Taking next-gen mAbs to new heights will lead modality innovation
Execs and investors weigh in on which technologies will yield the biggest gains in innovation in the near term and beyond: BioCentury survey
BioCentury | Nov 3, 2023
Management Tracks
Prokarium hires Henry as COO
Plus: Actinium hires Bodarky and updates from Summit, CentiVax, vTv and Calidi
BioCentury | Oct 3, 2023
Management Tracks
Affibody names Peter Zerhouni CFO
Plus: Restructuring at Kezar as CEO, CMO step down, and updates from Atomwise, Aura, Twist, Acelyrin and more
BioCentury | Aug 14, 2023
Management Tracks
Gardner named CEO of Flagship’s Ampersand
Plus: Brian Powl joins Kura as CCO, and updates from BioNTech, Allogene, CG and more
Items per page:
1 - 10 of 178